Tuberculosis Research and Treatment

Tuberculosis Research and Treatment / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 3404860 | https://doi.org/10.1155/2016/3404860

Mitchell A. Yakrus, Jeffrey Driscoll, Allison McAlister, David Sikes, Denise Hartline, Beverly Metchock, Angela M. Starks, "Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States", Tuberculosis Research and Treatment, vol. 2016, Article ID 3404860, 5 pages, 2016. https://doi.org/10.1155/2016/3404860

Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States

Academic Editor: Isamu Sugawara
Received07 Apr 2016
Accepted15 May 2016
Published08 Jun 2016

Abstract

Ethambutol (EMB) is used as a part of drug regimens for treatment of tuberculosis (TB). Susceptibility of Mycobacterium tuberculosis complex (MTBC) isolates to EMB can be discerned by DNA sequencing to detect mutations in the embB gene associated with resistance. US Public Health Laboratories (PHL) primarily use growth-based drug susceptibility test (DST) methods to determine EMB resistance. The Centers for Disease Control and Prevention (CDC) provides a service for molecular detection of drug resistance (MDDR) by DNA sequencing and concurrent growth-based DST using agar proportion. PHL and CDC test results were compared for 211 MTBC samples submitted to CDC from September 2009 through February 2011. Concordance between growth-based DST results from PHL and CDC was 88.2%. A growth-based comparison of 39 samples, where an embB mutation associated with EMB resistance was detected, revealed a higher percentage of EMB resistance by CDC (84.6%) than by PHL (59.0%) which was significant ( value = 0.002). Discordance between all growth-based test results from PHL and CDC was also significant ( value = 0.003). Most discordance was linked to false susceptibility using the BACTEC MGIT 960 (MGIT) growth-based system. Our analysis supports coalescing growth-based and molecular results for an informed interpretation of potential EMB resistance.

1. Introduction

In 2014, 9,412 new tuberculosis (TB) cases were reported in the United States [1]. Of these cases, 96 (1.3%) were classified as multidrug resistant (MDR), defined as resistance to at least rifampin (RMP) and isoniazid (INH). Reliable drug susceptibility testing (DST) for isolates of Mycobacterium tuberculosis complex (MTBC) is essential for selection of effective treatment regimens, interruption of transmission, and prevention of further development of resistant forms of TB.

Ethambutol (EMB) in combination with INH, RMP, and pyrazinamide (PZA) is used as part of a first-line antituberculosis drug regimen for patients with drug-susceptible TB. EMB is often included, in combination with second-line drugs, as part of the treatment regimen for MDR-TB when the isolate is susceptible [24]. EMB is a bacteriostatic antimicrobial that interferes with cellular metabolism by inhibition of arabinosyltransferase required for biosynthesis of arabinogalactan in the cell wall [4, 5]. Mutations at the embCAB operon, which encode mycobacterial arabinosyltransferase, are significantly associated with growth-based resistance to EMB [6]. These mutations are most frequently reported at either embB codon 306 or embB codon 406 [79].

Nonsynonymous mutations have been detected at other codons outside these locations between codons 296 and 497 in EMB-resistant isolates [10]. However, mutations reported at these codons, such as Glu378Ala, may be lineage markers not associated with resistance [1114]. Therefore, DNA sequencing alone cannot be relied upon to detect EMB resistance due to the presence of mutations not conferring growth-based resistance and because other mechanisms of EMB resistance may exist [13, 14]. Discordant results among test methods of growth-based DST for EMB resistance have been well documented and linked to difficulties establishing equivalent critical concentrations (CC) [7, 1519]. In addition, allelic exchange experiments have demonstrated that some embB 306 mutations, such as Met306Ile, may result in only a moderately raised minimal inhibitory concentration (MIC) above the CC and MTBC isolates with these mutations may be falsely reported as susceptible [8, 20]. Both EMB-susceptible and EMB-resistant isolates with Met306Ile mutations were reported in the same study where agar proportion was used for growth-based DST [13].

The Centers for Disease Control and Prevention (CDC) provides molecular detection of drug resistance (MDDR) through DNA sequencing of loci associated with TB-drug resistance, including EMB resistance, and concurrent growth-based DST. Molecular testing can be performed with either MTBC isolates or sediments of clinical specimens that are positive for MTBC by nucleic acid amplification tests (NAAT) [13]. This service is available upon request by public health laboratories (PHL) for samples meeting defined submission criteria [21]. PHL submitting MTBC samples for testing receive an interim report with molecular results and a final report upon completion of growth-based DST. The final report contains interpretive comments based on both molecular and growth-based results. CDC’s MDDR service has been described previously [22, 23].

Previously, we examined the concordance between molecular and growth-based DST for detection of RIF and INH resistance of MTBC samples submitted to CDC’s MDDR service [23]. In this study, we compared EMB susceptibility results from the MDDR service, molecular and growth-based, with growth-based results provided by PHL. In addition, we analyzed test results and methods for probable causes of discordance.

2. Materials and Methods

2.1. MTBC Samples and Collection of Growth-Based DST Results from PHL

EMB test results analyzed for this study were MTBC isolates and NAAT-positive sediments from TB patients submitted by PHL to CDC’s MDDR service from September 2009 to February 2011. Growth-based DST results and test methods used for these samples at PHL were available from a previously described study that used a secure survey instrument to collect data online from PHL [23, 24]. CDC determined that the prior study was not human subjects’ research; thus, it did not require Institutional Review Board review. Growth-based DST results for EMB were successfully collected for 211 MTBC samples submitted by PHL during the study timeframe. Collection of all data was approved under an Office of Management and Budget (OMB) generic clearance package (Information Collections to Advance State, Tribal, Local and Territorial Governmental Agency System Performance, Capacity, and Program Delivery; OMB number 0920-0879) as required under the Paperwork Reduction Act.

2.2. Growth-Based DST and DNA Sequencing

Growth-based DST for EMB was performed at CDC using the indirect agar proportion method using a critical concentration (CC) of 5 μg/mL in supplemented Middlebrook 7H10 agar [25]. PHL performed growth-based DST on 211 MTBC samples submitted to CDC’s MDDR using either BACTEC MGIT 960 (MGIT) system (Becton Dickinson and Company) (136 samples), BACTEC 460 (Becton Dickinson and Company) (45 samples), BACTEC 460 and agar proportion (18 samples), agar proportion (2 samples), VersaTrek (Trek Diagnostic Systems) (1 sample), or isolates that were referred to another laboratory (9 samples) where the DST method was unknown. DNA sequencing for detection of mutations at the embB locus associated with EMB drug resistance was performed as previously described [13].

2.3. Data Analysis

Growth-based DST data from PHL were analyzed using PASW Statistics (version 18; IBM SPSS software). Concordance between testing at CDC (both DNA sequencing and growth-based DST) and growth-based testing performed by PHL was determined by cross-tabulation of results and calculation of percent agreement. Sample proportions were compared using McNemar’s test without continuity correction with a significance level of value = 0.05.

3. Results and Discussion

3.1. Comparison of Growth-Based DST Performed by PHL with DNA Sequencing and Growth-Based DST Performed by CDC

The cross-tabulation of results for determination of EMB resistance from growth-based DST from PHL and from DNA sequencing and growth-based DST performed by CDC is shown in Table 1. Of the 211 MTBC samples submitted by PHL with a corresponding growth-based DST result for EMB, a growth-based DST result was not available for comparison from 30 samples tested by CDC. Absence of growth-based DST results was due to either contamination (14 samples) or failure to grow (16 samples). DNA sequencing was not performed at CDC for 12 samples submitted in 2009 before molecular testing for EMB resistance was added. CDC detected 14 MTBC samples that contained either Glu378Ala or Leu355Leu neutral polymorphisms confirmed to be EMB-susceptible by CDC agar proportion. PHL growth-based EMB results and DNA sequencing and growth-based results from CDC were available for comparison for 170 of the 211 MTBC samples listed in Table 1. There was agreement between growth-based DST results from both PHL and CDC for 150 samples resulting in an overall agreement of 88.2%.


PHL growth-based DST result for EMBCDC molecular result for embB (amino acid change)CDC’s agar proportion result (number of MTBC samples)
ResistantSusceptibleNo growthContaminatedTotal number of samples

ResistantMet306Ile40307
Met306Ile, Asp328Gly00101
Met306Ile, Gly406Ala10001
Met306Val903113
Phe330Leu10001
Tyr334His20002
Ser347Thr10001
Asp354Ala20103
Glu378Ala01001
Gly406Ala20002
Gly406Asp10001
No mutation43018
Not performed20002

SusceptibleGly294Gly01001
Asn296Tyr10001
Met306Ile21104
Met306Val40004
Val309Ile00101
Leu355Leu01001
Leu355Leu, Glu378Ala03003
Glu378Ala094215
Gly406Ala02002
Gly406Cys21003
Gly406Ser10001
No mutation610529122
Not performed090110

Total451361614211

PHL: public health laboratory; DST: drug susceptibility testing; CDC: Centers for Disease Control and Prevention; EMB: ethambutol; MTBC: Mycobacterium tuberculosis complex.

Cross-tabulation of whether or not an embB mutation associated with EMB resistance was detected using DNA sequencing of MTBC samples by CDC with the number resistant by growth-based DST at both PHL and CDC is shown in Table 2. DNA sequencing determined that 39 samples (22.9%) of the 170 MTBC samples with growth-based results available from both PHL and CDC contained an embB mutation associated with resistance. When an embB mutation associated with resistance was detected, a higher percentage (84.6%) of these samples were found to be resistant using growth-based DST at CDC by agar proportion compared with growth-based DST performed by PHL (59.0%), and this difference was significant ( value = 0.002). There was no significant difference in growth-based DST results between CDC and PHL for MTBC samples where no mutation was detected ( value = 0.317). However, for all 170 MTBC samples examined, there was a significant difference ( value = 0.003) between growth-based determination of EMB resistance performed by PHL and that performed by CDC.


Detection of embB mutation by CDC’s MDDRNumber of samplesNumber of EMB-resistant MTBC samples (%) value
PHL growth-based DSTCDC agar proportion

Yes3923 (59.0)33 (84.6)0.002
No1317 (5.34)10 (7.63)0.317

Total17030 (17.6)43 (25.3)0.003

Including samples with Glu378Ala and Leu355Leu polymorphisms not associated with EMB resistance.
CDC: Centers for Disease Control and Prevention; PHL: public health laboratory; DST: drug susceptibility testing; EMB: ethambutol; MTBC: Mycobacterium tuberculosis complex; MDDR: molecular detection of drug resistance.
3.2. Discordance between Growth-Based DST Performed by PHL and CDC

Discordant results between PHL and CDC including DST methods used are listed in Table 3. There were 20 discordant test results between growth-based DST performed by PHL and agar proportion performed by CDC of which 16 (80%) samples were found to be susceptible to EMB by PHL and resistant to EMB by CDC. The growth-based DST method most frequently used by PHL among these 16 samples was MGIT (11 samples). For 10 of these 16 samples, testing by CDC detected embB mutations associated with EMB resistance at either codon 306 (6 samples), codon 406 (3 samples), or codon 296 (1 sample). For the six other discordant results in this category, DNA sequencing by CDC did not detect an embB mutation. However, it has been reported that MTBC isolates may be EMB-resistant using agar proportion without molecular detection of an embB mutation [13, 26]. For three of the MTBC samples with discordant results, PHL reported EMB resistance using MGIT while molecular testing by CDC did not detect an embB mutation and these samples were susceptible using agar proportion. PHL also reported EMB resistance using MGIT for one sample where molecular testing at CDC detected a mutation not associated with embB resistance at codon 378 (Glu378Ala) and found it to be EMB-susceptible by agar proportion.


Number of samplesPHL growth-based DST resultPHL growth-based DST methodembB mutation detected by CDC’s MDDRCDC’s agar proportion result

1Susceptible BACTEC 460 and agar proportion Asn296Tyr Resistant
1Susceptible MGIT 960Met306Ile Resistant
1Susceptible BACTEC 460 and agar proportion Met306Ile Resistant
3Susceptible MGIT 960Met306Val Resistant
1SusceptibleBACTEC 460Met306ValResistant
1ResistantMGIT 960Glu378AlaSusceptible
2SusceptibleMGIT 960Gly406CysResistant
1SusceptibleNot performed in-houseGly406SerResistant
3ResistantMGIT 960NoneSusceptible
5SusceptibleMGIT 960NoneResistant
1SusceptibleNot performed in-houseNoneResistant

PHL: public health laboratory; DST: drug susceptibility testing; CDC: Centers for Disease Control and Prevention; MDDR: molecular detection of drug resistance.

Combined molecular and growth-based test results from CDC suggest that most discordance with PHL growth-based DST was due to false susceptibility to EMB. False susceptibility to EMB may occur for various reasons. Some EMB-resistant strains grow better on solid media versus liquid media (such as media used with the MGIT system) [16, 18]. Therefore, even though the recommended CC for determining primary resistance to EMB for MGIT and agar proportion are both 5 μg/mL, these test concentrations may not be equivalent when comparing results using these test methods [27]. Specific mutations may affect the MIC of the isolate such that the variability around the CC is due to the MIC being close to the CC, thus affecting false susceptibility in MGIT. Heteroresistance may be present with late growth of resistant mutants on solid media in the presence of EMB with failure to detect these mutants in the liquid-based MGIT system due to lack of growth [17].

4. Conclusions

Most laboratories rely on a single growth-based DST method such as the well-established MGIT system. Though the MGIT system has been found to be reliable for growth-based DST of MTBC isolates for most antituberculosis drugs, this study and previous reports have found discrepant results when this method is used solely for determination of EMB resistance [16, 18, 19, 28]. By providing both molecular detection and growth-based DST by agar proportion, CDC’s MDDR detected a significantly higher number of MTBC samples that were EMB-resistant than PHL that employed only growth-based methods. Our results reinforce the importance of combining molecular testing with a reliable method of growth-based DST for accurate detection of EMB-resistant TB.

Disclosure

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

Acknowledgments

The authors gratefully acknowledge the data contributions of public health laboratories.

References

  1. Centers for Disease Control and Prevention, “Tuberculosis trends—United States, 2014,” Morbidity and Mortality Weekly Report, vol. 64, no. 6, pp. 264–269, 2014. View at: Google Scholar
  2. Centers for Disease Control and Prevention, “Treatment of tuberculosis,” Morbidity and Mortality Weekly Report, vol. 52, pp. 1–77, 2003. View at: Google Scholar
  3. J. A. Caminero, G. Sotgiu, A. Zumla, and G. B. Migliori, “Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 621–629, 2010. View at: Publisher Site | Google Scholar
  4. Partners in Health, “The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis,” 2014, http://parthealth.3cdn.net/b0233c0e1e4088e07b_unm6vyf2f.pdf. View at: Google Scholar
  5. K. Takayama and J. O. Kilburn, “Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis,” Antimicrobial Agents and Chemotherapy, vol. 33, no. 9, pp. 1493–1499, 1989. View at: Publisher Site | Google Scholar
  6. K. Mikusova, R. A. Slayden, G. S. Besra, and P. J. Brennan, “Biogenesis of the mycobacterial cell wall and the site of action of ethambutol,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 11, pp. 2484–2489, 1995. View at: Publisher Site | Google Scholar
  7. A. Telenti, W. J. Philipp, S. Sreevatsan et al., “The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol,” Nature Medicine, vol. 3, no. 5, pp. 567–570, 1997. View at: Publisher Site | Google Scholar
  8. A. M. Starks, A. Gumusboga, B. B. Plikaytis, T. M. Shinnick, and J. E. Posey, “Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 3, pp. 1061–1066, 2009. View at: Publisher Site | Google Scholar
  9. C. Plinke, H. S. Cox, N. Zarkua et al., “embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 7, pp. 1359–1367, 2010. View at: Publisher Site | Google Scholar
  10. F. Brossier, W. Sougakoff, C. Bernard et al., “Molecular analysis of the embCAB locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 8, pp. 4800–4808, 2015. View at: Publisher Site | Google Scholar
  11. R. Shi, J. Zhang, K. Otomo, G. Zhang, and I. Sugawara, “Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 12, pp. 4515–4517, 2007. View at: Publisher Site | Google Scholar
  12. F. Brossier, N. Veziris, A. Aubry, V. Jarlier, and W. Sougakoff, “Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates,” Journal of Clinical Microbiology, vol. 48, no. 5, pp. 1683–1689, 2010. View at: Publisher Site | Google Scholar
  13. P. J. Campbell, G. P. Morlock, R. D. Sikes et al., “Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 2032–2041, 2011. View at: Publisher Site | Google Scholar
  14. S. V. Ramaswamy, A. G. Amin, S. Göksel et al., “Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 2, pp. 326–336, 2000. View at: Publisher Site | Google Scholar
  15. B. Madison, B. Robinson-Dunn, I. George et al., “Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods,” Journal of Clinical Microbiology, vol. 40, no. 11, pp. 3976–3979, 2002. View at: Publisher Site | Google Scholar
  16. A. Krüüner, M. D. Yates, and F. A. Drobniewski, “Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 44, no. 3, pp. 811–818, 2006. View at: Publisher Site | Google Scholar
  17. Z. Zhang, Y. Wang, Y. Pang, and K. M. Kam, “Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates,” Journal of Clinical Microbiology, vol. 52, no. 2, pp. 638–641, 2014. View at: Publisher Site | Google Scholar
  18. S. Banu, S. M. M. Rahman, M. S. R. Khan et al., “Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory,” Journal of Clinical Microbiology, vol. 52, no. 1, pp. 156–163, 2014. View at: Publisher Site | Google Scholar
  19. S. Christianson, D. Voth, J. Wolfe, and M. K. Sharma, “Re-evaluation of the critical concentration for ethambutol antimicrobial sensitivity testing on the MGIT 960,” PLoS ONE, vol. 9, no. 9, Article ID e108911, 2014. View at: Publisher Site | Google Scholar
  20. C. Plinke, K. Walter, S. Aly, S. Ehlers, and S. Niemann, “Mycobacterium tuberculosisembB codon 306 mutations confer moderately increased resistance to ethambutol In vitro and In vivo,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 6, pp. 2891–2896, 2011. View at: Publisher Site | Google Scholar
  21. Centers for Disease Control and Prevention, Molecular Detection of Drug Resistance Request Form, 2013, http://www.cdc.gov/tb/topic/laboratory/MDDRsubmission form.pdf.
  22. J. Driscoll, A. Lentz, D. Sikes, and B. Metchock, “The first month of a new diagnostic service for the molecular detection of MDR and XDR tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 181, Article ID A2259, 2010. View at: Google Scholar
  23. M. A. Yakrus, J. Driscoll, A. J. Lentz et al., “Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States,” Journal of Clinical Microbiology, vol. 52, no. 6, pp. 1932–1937, 2014. View at: Publisher Site | Google Scholar
  24. SnapSurveys, Version Snap 10 Professional, SnapSurveys, Portsmouth, NH, USA, 2009.
  25. Clinical and Laboratory Standards Institute, “Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard,” CLSI Document M24A2E, Clinical and Laboratory Standards Institute (CLSI), Wayne, Pa, USA, 2011. View at: Google Scholar
  26. F. Alcaide, G. E. Pfyffer, and A. Telenti, “Role of embB in natural and acquired resistance to ethambutol in mycobacteria,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 10, pp. 2270–2273, 1997. View at: Google Scholar
  27. F. Ardito, B. Posteraro, M. Sanguinetti, S. Zanetti, and G. Fadda, “Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 39, no. 12, pp. 4440–4444, 2001. View at: Publisher Site | Google Scholar
  28. E. Cambau, M. Viveiros, D. Machado et al., “Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study,” Journal of Antimicrobial Chemotherapy, vol. 70, no. 3, Article ID dku438, pp. 686–696, 2015. View at: Publisher Site | Google Scholar

Copyright © 2016 Mitchell A. Yakrus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views2125
Downloads655
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.